What is it? Why is it important?

How to submit an amendment depends on the type of amendment, thus whether it is a:

  • Safety amendment, or
  • Substantial (SA), or
  • Non-substantial amendment (N-SA)

 

Except for safety amendments, substantial amendments must be approved prior to implementation, and are submitted to the:

  • Ethics Committee (EC) for all studies under HRA
  • Swissmedic for:
  • FOPH for:
    • Transplantation studies of human organs, tissues and cells, or
    • Transplantation studies of embryonic of foetal tissues and cells

 

Non-substantial amendments are reported to:

  • Swissmedic for risk-category B and C studies as soon as possible
  • The EC in the annual safety report

 

To protect study participant, urgent protective safety measures are implemented prior to Swissmedic and EC approval. Still, they must be notified as soon as possible.

What do I need to do?

As a SP-INV and Site-INV:

  • In the event of a required safety amendment, immediately or as soon as possible:
    • Implement preventative safety measures
    • Notify the EC and if applicable Swissmedic

 

As a SP-INV:

  • Check the Swissmedic and EC homepage to determine whether a planned amendment is a SA or N-SA
  • Define reason(s) why you think an amendment is necessary
  • Adapt documents affected by the amendment and:
    • Ensure original text remains legible by using track-change mode
    • Create a “clean” version

 

Submit SAs to:

  • EC via BASEC (electronic submission): Access “manage my applications” and upload amended documents (e.g. include both clean and track-changed versions)
  • To Swissmedic using one of the following options:
    • Electronic submission via the KLV portal (zip file with documents in eDok folder structure)
    • Electronic submission by postal mail (e.g. “FO submission form” and CD/DVD)
    • Paper submission by postal mail (e.g. paper documents and CD/ DVD)

More

When submitting a full paper option to Swissmedic ensure it is well organised:

  • Based on the scope of your amendment, create a binder with applicable sections using eDok folder structure. File documents accordingly
  • For submission place:
    • Individual documents in a folder
    • Large quantities of documents in a binder using dividers
  • For the submission dossier, include both the folder/binder (paper copy) and CD/DVD (electronic copy)

 

In your cover letter, include information that could not be included in the FO submission form. Once the dossier has been received by Swissmedic, they will forward an acknowledgement of receipt.

Where can I get help?

Your local Research Support Centre can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

External Links

Swissethics – see in particular

  • Substantial amendment: YES or NO or "it depends"
  • BASEC: the EC submission portal

Swissmedic – see in particular

  • Human medicines / Clinical trials / Clinical trials on medicinal products / Submission of changes during the clinical trial and reporting
  • BW101_10_003e_MB Guideline amendments clinical trials
  • FO-template: BW101_10_019e_FO confirmation electronic submission

References

ICH GCP R(3) – see in particular articles and Appendix

  • Glossary: Definition Protocol amendment
  • Appendix B. Clinical trial protocol and protocol amendment(s)
  • Art. 1.2.2a IRB / IEC Responsibility
  • 1.4.7 Changes to the protocol
  • 2.5.5 Reporting of an amendment
  • 3.13.3 Managing an immediate hazard

ICH E8(R1) – see in particular guidelines

  • 6.1.1 Protocol adherence

Swiss Law

ClinO – see in particular articles and annexes

  • Art. 29 Modifications (EC)
  • Art. 34 Modifications (Swissmedic)
  • Art. 55-56 Modifications (FOPH)
  • Annex 3 EC submission
  • Annex 4 Swissmedic and FOPH submission

ClinO-MD – see in particular articles

  • Art. 15 Modifications (EC)
  • Art. 20 Modifications (Swissmedic)

HRO – see in particular article and annex

  • Art. 18 Modifications
  • Annex 2 EC submission
Abbreviations
  • BASEC – Business Administration System for Ethics Committees
  • ClinO – Clinical Trials Ordinance
  • ClinO-MD – Ordinance on Clinical Trials with Medical Devices
  • CTU – Clinical Trials Unit
  • EC – Ethics Committee
  • FOPH – Federal Office of Public Health
  • HRA – Human Research Act
  • HRO – Human Research Ordinance
  • ICH – International Council for Harmonisation
  • ICH GCP – International Council for Harmonisation - Good Clinical Practice
  • IMP – Investigational Medicinal Product
  • KLV – Klinische Versuche
  • N-SA – Non Substantial Amendment
  • SA – Substantial Amendment
  • Site-INV – Site Investigator
  • SP-INV – Sponsor Investigator
Conduct ↦ Ethics and Laws ↦ Amendment ↦ Submission
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Conduct ↦ Ethics and Laws ↦ Amendment ↦ Submission